OSI Pharmaceuticals and Genentech’s Tarceva Non-Small Cell Lung Cancer Therapy
November 18, 2004 by admin · Leave a Comment
On November 18, 2004 OSI Pharmaceuticals and Genentech, Inc. announced that the FDA had approved their cancer therapeutic Tarceva™ (erlotinib). The oral tablet is intended for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. The FDA’s approval of Tarceva was based on results [...]